C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)

Completed · Phase 3

Conditions studied: Hereditary Angioedema

In brief

Hereditary angioedema (HAE) is a rare disorder characterized by congenital lack of functional C1 esterase inhibitor. If not treated adequately, the acute attacks of HAE can be life-threatening and may even result in fatalities, especially in case of involvement of the larynx.The planned extension study is designed to enrol subjects that participated in the pivotal study in order to provide them with C1-INH for treatment of acute HAE attacks for 24 months or until the licensing procedure for C1-INH is finalized, whatever comes first.

Key facts

Study ID
NCT00292981
Run by
CSL Behring
People needed
57
Starts
2005-08-01
Expected to finish
2010-05-01
Last updated by the study team
2015-05-07

Who can join

Age: 6 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.